Evoke Pharma, Inc. (EVOK)
NASDAQ: EVOK · IEX Real-Time Price · USD
0.475
+0.044 (10.21%)
At close: May 31, 2024, 4:00 PM
0.490
+0.015 (3.12%)
After-hours: May 31, 2024, 4:45 PM EDT
Company Description
Evoke Pharma, Inc., a specialty pharmaceutical company, primarily focuses on the development and commercialization of drugs for the treatment of gastroenterological disorders and diseases.
It offers Gimoti, a metoclopramide nasal spray to treat symptoms associated with acute and recurrent diabetic gastroparesis in adults.
The company markets its products to gastroenterologists, internal medicine specialists, primary care physicians, and select health care providers.
Evoke Pharma, Inc. was incorporated in 2007 and is headquartered in Solana Beach, California.
Evoke Pharma, Inc.
Country | United States |
Founded | 2007 |
IPO Date | Sep 25, 2013 |
Industry | Drug Manufacturers - Specialty & Generic |
Sector | Healthcare |
Employees | 4 |
CEO | Matthew J. D'Onofrio MBA |
Contact Details
Address: 420 Stevens Avenue, Suite 370 Solana Beach, California 92075 United States | |
Phone | 858-345-1494 |
Website | evokepharma.com |
Stock Details
Ticker Symbol | EVOK |
Exchange | NASDAQ |
Fiscal Year | January - December |
Reporting Currency | USD |
CIK Code | 0001403708 |
CUSIP Number | 30049G104 |
ISIN Number | US30049G2030 |
Employer ID | 20-8447886 |
SIC Code | 2834 |
Key Executives
Name | Position |
---|---|
Matthew J. D'Onofrio MBA | Co-Founder, President, Chief Executive Officer, Chief Operating Officer, Secretary, Treasurer and Director |
Dr. Marilyn R. Carlson D.M.D., M.D., RAC. | Chief Medical Officer |
Christopher Quesenberry | Chief Commercial Officer - Gimoti (TM) |
Latest SEC Filings
Date | Type | Title |
---|---|---|
May 28, 2024 | 8-K | Current Report |
May 15, 2024 | DEFA14A | Additional definitive proxy soliciting materials and Rule 14(a)(12) material |
May 14, 2024 | ARS/A | Filing |
May 14, 2024 | 10-Q | Quarterly Report |
May 14, 2024 | 8-K | Current Report |
May 14, 2024 | 10-K/A | [Amend] Annual report |
May 14, 2024 | 8-K | Current Report |
Apr 10, 2024 | ARS | Filing |
Apr 10, 2024 | DEFA14A | Additional definitive proxy soliciting materials and Rule 14(a)(12) material |
Apr 10, 2024 | DEF 14A | Other definitive proxy statements |